T3 vs. T4 Thyroid Hormone: Which One Should You Be Taking?

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

The thyroid gland produces two primary hormones: Thyroxine (T4) and Triiodothyronine (T3). While T4 is the more abundant hormone, T3 is the biologically active form that directly influences cellular metabolism. The debate over whether to supplement with T4 alone, or a combination of T4 and T3, is central to optimizing thyroid treatment, particularly for patients who continue to experience symptoms despite "normal" TSH levels on T4 monotherapy.

The thyroid gland produces two primary hormones: Thyroxine (T4) and Triiodothyronine (T3). While T4 is the more abundant hormone, T3 is the biologically active form that directly influences cellular metabolism. The debate over whether to supplement with T4 alone, or a combination of T4 and T3, is central to optimizing thyroid treatment, particularly for patients who continue to experience symptoms despite "normal" TSH levels on T4 monotherapy.

The Physiology of Thyroid Hormones

The thyroid gland primarily secretes T4 (approximately 80%) and a smaller amount of T3 (approximately 20%). T4 is considered a prohormone, meaning it must be converted into T3 to exert its effects. This conversion primarily occurs in peripheral tissues, such as the liver, kidneys, and muscles, through the action of deiodinase enzymes (D1, D2, D3).

• T4 (Levothyroxine): This is the most commonly prescribed thyroid hormone replacement. It has a longer half-life (about 7 days), providing stable hormone levels. The body then converts T4 into T3 as needed.
• T3 (Liothyronine): This is the active form of thyroid hormone. It has a shorter half-life (about 1 day), leading to more fluctuating levels if taken once daily. T3 directly binds to nuclear receptors, initiating metabolic processes.

The Argument for T4 Monotherapy

Standard medical practice largely favors T4 monotherapy (e.g., Synthroid, Levoxyl) for hypothyroidism. The rationale is that the body can efficiently convert T4 to T3, thus providing all necessary thyroid hormones in a physiological manner. This approach is supported by:

• Stable Levels: T4's long half-life allows for once-daily dosing and stable serum concentrations.
• Physiological Conversion: The body's ability to regulate T4 to T3 conversion is seen as an advantage, allowing for fine-tuning of active hormone levels based on tissue demands.
• Extensive Research: Levothyroxine has been extensively studied and proven effective in normalizing TSH and alleviating hypothyroid symptoms in a majority of patients [1].

The Case for Combination T4/T3 Therapy

Despite the widespread use of T4 monotherapy, a significant subset of patients (estimated 10-20%) continue to experience persistent hypothyroid symptoms, such as fatigue, brain fog, weight gain, and depression, even when their TSH levels are within the reference range. This has led to a growing interest in combination T4/T3 therapy.

Arguments for combination therapy include:

• Impaired Conversion: Some individuals may have genetic polymorphisms (e.g., in deiodinase enzymes) or other factors (e.g., chronic stress, inflammation, nutrient deficiencies) that impair their ability to convert T4 to T3 effectively. In these cases, T4 monotherapy may not provide adequate active T3 at the cellular level [2].
• Improved Symptom Scores: Several studies and meta-analyses have shown that a subset of patients prefer combination T4/T3 therapy over T4 monotherapy, reporting improvements in mood, energy levels, and cognitive function [3].
• Physiological Ratios: Natural Desiccated Thyroid (NDT) contains both T4 and T3 in a ratio similar to human thyroid glands, along with T2 and calcitonin. Proponents argue this provides a more "complete" hormone replacement.

Who Might Benefit from T4/T3 Combination?

Consideration for T4/T3 combination therapy or NDT is typically given to patients who:

• Have persistent hypothyroid symptoms despite optimal TSH on T4 monotherapy.
• Have low Free T3 levels despite normal Free T4 and TSH.
• Exhibit genetic variations affecting deiodinase activity.
• Report a subjective improvement in well-being on combination therapy.

Typical starting doses for combination therapy might involve adding 5-10 mcg of liothyronine (T3) to the existing levothyroxine dose, often split into two daily doses due to T3's shorter half-life. NDT dosing is more complex and requires careful titration based on clinical response and lab values.

Monitoring and Cautions

Regardless of the chosen therapy, careful monitoring is essential. For T4 monotherapy, TSH and Free T4 are primary. For combination therapy, TSH, Free T4, and Free T3 should all be monitored. The goal is to achieve symptom resolution while keeping TSH within the reference range (often aiming for 0.5-2.5 mIU/L) and Free T3 in the upper half of its reference range.

Excessive T3 can lead to symptoms of hyperthyroidism, such as palpitations, anxiety, and bone loss. Therefore, close collaboration with a knowledgeable practitioner is crucial to individualize treatment and ensure safety and efficacy.

References

[1] Biondi, B., & Cooper, D. S. (2008). Benefits of thyroxine replacement therapy in subclinical hypothyroidism: a literature review. Journal of Clinical Endocrinology & Metabolism, 93(5), 1772-1779. https://doi.org/10.1210/jc.2007-2409

[2] Wiersinga, W. M. (2014). T4 + T3 combination therapy: is there a future? Thyroid, 24(1), 1-2. https://doi.org/10.1089/thy.2013.0409

[3] Saravanan, P., et al. (2002). Psychological well-being in patients on 'adequate' doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clinical Endocrinology, 57(5), 577-585. https://doi.org/10.1046/j.1365-2265.2002.01632.x